New Weekly Diabetes Drug Gets FDA Nod

Recently approved by the FDA, dulaglutide (Trulicity) is a once-a-week injectable, single-dose pen that has been shown to safely improve blood sugar levels in six separate trials of more than 3,300 people with type 2 diabetes. The medication, which requires no mixing (as do competing drugs), can be used alone or in combination with other diabetes medication, including metformin and mealtime insulin. Potential side effects include nausea, diarrhea and abdominal pain. People at risk for thyroid or endocrine gland tumors should not take dulaglutide.